Start Time: 08:30 January 1, 0000 8:58 AM ET

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI)

Q3 2023 Earnings Conference Call

November 14, 2023, 08:30 AM ET

Company Participants

Chaim Lebovits - President and CEO

Stacy Lindborg - Co-CEO

Alla Patlis - Interim CFO

Michael Wood - LifeSci Advisors

Conference Call Participants

David Bautz - Zacks Small-Cap Research

Operator

Greetings, and welcome to the BrainStorm Cell Therapeutics Third Quarter 2023 Earnings Call. At this time, participants are in a listen-only mode. As a reminder, this call is being recorded.

And I would now like to introduce your host for today's call, Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.

Michael Wood

Good morning and thank you everybody for joining us. Earlier today, BrainStorm issued a press release with its financial results for the third quarter of 2023, including a corporate update.

Before passing it off to the company management for prepared remarks, I’d like to remind listeners on this conference call will contain numerous statements, descriptions, forecasts and projections regarding BrainStorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative disorders, such as ALS, the sufficiency of the company's existing capital resources for continuing operations in 2023 and beyond, the safety and clinical effectiveness of NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, as well as the company's ability to develop strategic collaborations and partnerships to support its business planning efforts.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond BrainStorm's control, including the risks and uncertainties described from time-to-time in the company's SEC filings. The company's results may differ materially from those projected on today's call and the company undertakes no obligation to publicly update any forward-looking statements.

Joining us on the call today morning will be Mr. Chaim Lebovits, President and CEO of BrainStorm; Dr. Stacy Lindborg, Co-Chief Executive Officer; and Alla Patlis, Interim Chief Financial Officer.

So I'd now like to turn the call over to Mr. Lebovits. Please go ahead, Chaim.

Chaim Lebovits

Thank you, Michael. Thanks to all who have joined us to discuss our Q3 2023 financial results and ongoing progress. We are committed to our goal of making NurOwn available to the ALS community. Our priority now is to work with the FDA and do everything in our power to align in a path forward.